Profund Advisors LLC Raises Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Profund Advisors LLC raised its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 24.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 36,542 shares of the biotechnology company’s stock after acquiring an additional 7,108 shares during the quarter. Profund Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $2,426,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ARWR. Arrowstreet Capital Limited Partnership boosted its position in Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after buying an additional 2,017,489 shares during the period. Deerfield Management Company L.P. purchased a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $34,249,000. Balyasny Asset Management L.P. purchased a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $27,349,000. Pictet Asset Management Holding SA boosted its position in Arrowhead Pharmaceuticals by 253.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,028,736 shares of the biotechnology company’s stock valued at $68,636,000 after buying an additional 737,713 shares during the period. Finally, Baker BROS. Advisors LP boosted its position in Arrowhead Pharmaceuticals by 77.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,670,762 shares of the biotechnology company’s stock valued at $57,625,000 after buying an additional 731,588 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares of the company’s stock, valued at $17,021,850. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. This trade represents a 5.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 36,065 shares of company stock valued at $2,554,562 over the last ninety days. Insiders own 3.60% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the subject of several recent analyst reports. Sanford C. Bernstein lifted their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada lifted their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. B. Riley Financial lifted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, May 6th. Finally, Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $87.80.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $73.18 on Wednesday. The stock has a market cap of $10.31 billion, a P/E ratio of -34.04 and a beta of 1.28. The company has a fifty day simple moving average of $66.41 and a 200-day simple moving average of $62.48. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $14.30 and a 12-month high of $82.26. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same period in the previous year, the company earned $2.75 earnings per share. Arrowhead Pharmaceuticals’s quarterly revenue was down 86.4% compared to the same quarter last year. Equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.